Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP1 | Q9NZ08 | 6/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.49 |
| ▸ | ANPEP | P15144 | 5/20 | 0.49 |
| ▸ | LAP3 | P28838 | 4/20 | 0.49 |
| ▸ | CPA1 | P15085 | 3/20 | 0.47 |
| ▸ | CPA2 | P48052 | 3/20 | 0.47 |
| ▸ | CPA4 | Q9UI42 | 3/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7051413 | 0.92 | GRIK1 (0.49) | ERAP1ERAP2ANPEPLAP3MMP1 | |
| SCHEMBL7049618 | 0.88 | ERAP1 (0.44) | ERAP1ERAP2ANPEPLAP3CPA1 | |
| SCHEMBL7050270 | 0.86 | ERAP2 (0.53) | ERAP1ERAP2ANPEPLAP3CPA1 | |
| SCHEMBL7051219 | 0.85 | FOLH1 (0.41) | MMP1 | |
| SCHEMBL7047064 | 0.82 | ERAP1 (0.43) | ERAP1ERAP2ANPEPLAP3CPA1 | |
| SCHEMBL5134279 | 0.81 | MMP13 (0.60) | ERAP1ERAP2ANPEPLAP3MMP1 | |
| SCHEMBL7047091 | 0.81 | SIRT5 (0.44) | ERAP1ERAP2ANPEPLAP3 | |
| SCHEMBL7048091 | 0.80 | RXFP1 (0.47) | ERAP1ERAP2ANPEPLAP3CPA1 | |
| SCHEMBL7050048 | 0.80 | ANPEP (0.46) | ERAP1ERAP2ANPEPLAP3CPA1 | |
| SCHEMBL5051239 | 0.79 | ERAP1 (0.58) | ERAP1ERAP2ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | ERAP1 74/4885ERAP2 192/4885ANPEP 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.